Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: A network meta-analysis

British Journal of Cancer

Volumn 110, Issue 10, 2014, Pages 2396-2404

  Zhu, Z ^a   Zhang, J ^a   Liu, Y ^a   Chen, M ^a   Guo, P ^b   Li, K ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LONG TERM CARE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION SICKNESS; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84900542817     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.197     Document Type: Article

References (95)

1. Al-Mamgani A, Van Putten WL, Heemsbergen WD, Van Leenders GJ, Slot A, Dielwart MF, Incrocci L, Lebesque JV (2008) Update of Dutch mul ticenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72(4): 980-988.
2. Al-Mamgani A Van Putten WL Van Der Wielen GJ Levendag PC Incrocci L 2011 Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: Long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial) Int J Radiat Oncol Biol Phys 79 4 1004-1012.
3. Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P, Pai H, Ludgate C (2010) Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinica lly localized prostate cancer An analysis of the 3-versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 76(1): 23-30.
4. Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongar i MG, Benassi M, Strigari L (2011) Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 79(4): 1 013-1021.
5. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, Marzi S, Landoni V, Fowler J, Strigari L (2010) A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78(1): 11-18.
6. Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnarò P, Pinzi V, Arcangeli G (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84(5): 1172-1178.
7. Armstrong JG, Gillham CM, Dunne MT, Fitzpatrick DA, Finn MA, Cannon ME, Taylor JC, O?Shea CM, Buckney SJ, Thirion PG (2011) A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal t herapy before radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 81(1): 35-45.
8. Ataman F, Zu rlo A, Artignan X, Van Tienhoven G, Blank LE, Warde P, Dubois JB, Jeanneret W, Keuppens F, Bernier J (2004) Late toxicity following conventional radiotherapy for prostate cancer: Analysis of the EORTC trial 22863. Eur J Cancer 40(11): 1674-1681.
9. Bauman G, Rumble R, Chen J, Loblaw A, Warde P (2012) Intensitymodulated radiotherapy in the treatment of prostate cancer. Clin Oncol 24(7): 461-473.
10. Beckendorf V, Guerif S, Le Prisé E, Cosset J-M, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud J-M (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80(4): 1056-1063.
11. Beckendorf V, Gué rif S, Le Prisé E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM ( 2004) The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60(4): 1056-1065.
12. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360(9327): 103-108.
13. Bolla M, De Reijke TM, Van Tienhoven G, Van Den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G (2009) Duration of androgen suppression in the treatment of prostate cancer. New Engl J Med 360(24): 2516-2527.
14. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kut en A, Sternberg C, Gil T (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 337(5): 295-300.
15. Bolla M, Van Tienhoven G , Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-ye ar results of an EORTC randomised study. Lancet Oncol 11(11): 1066-1073.
16. Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2011) Introduction to Meta-analysis. Wiley.com.
17. Bosco JL, Halpenny B, Berry DL (2012) Personal preferences and discordant prostate cancer treatment choice in an intervention trial of men newly diagnosed with localized prostate cancer. Health Qual Life Outcomes 10(1): 123.
18. Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, Dos Reis RB (2013) Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localize d prostate cancer: A systematic review and meta-analysis. Core Evidence 8: 1-13
19. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnarò P, Terzoli E, Cognetti F, Carlini P (2009) Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate ca ncer Cancer 115(15): 3446-3456.
20. Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Cli n Epidemiol 50(6): 683-691.
21. Caldwell DM, Welton NJ, Ades A (2010) Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsi stency. J Clin Epidemiol 63(8): 875-882.
22. Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, Joseph D, Matthews J, Franklin I, Atkinson C (2005) Delayed rectal and urinary symptomatology in patients treated for prostate cancer by r adiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol 77(2): 117-125.
23. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins J, Churchill R, Watanabe N, N akagawa A, Omori IM, McGuire H (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet 373(9665): 746-758.
24. Cooperberg MR Broering JM Carroll PR 2010 Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 7 1117-1123.
25. Cox J, Kaplan G. American Society for Therapeutic Radiolog y and Oncology Consensus Panel (1997) Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37: 1035-1041.
26. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5): 1341-1346.
27. Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G (2004) Report of a multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically l ocalized prostate cancer. Int J Radiat Oncol Biol Phys 60(1): 15-23.
28. Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G (2009) Final report of multicent er Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 73(2): 327-333.
29. Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nisticò C, Ruggeri E, Sperduti I, Bracarda S, Pinnarò P (2010) Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate ca ncer: Meta-analysis of randomized trials. BMC Cancer 10(1): 675.
30. D?Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW (2004) 6-month androgen suppression plus radiation th erapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA 292(7): 821-827.
31. Dearnaley D, Hall E, Lawrence D, Huddart R, Eeles R, Nutting C, Gadd J, Warring ton A, Bidmead M, Horwich A (2005) Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92(3): 488-498.
32. Dearnaley D, S yndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13(1): 43-54.
33. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Mil lar J (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6): 475-487.
34. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiat ion Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6(11): 841-850.
35. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spr y NA (2011) Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 12(5): 451-459.
36. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3): 177-188.
37. Dias S, Sutton AJ, Welton NJ, Ades A (2011) NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, meta-regression, bias and bias-adjustment: Forthcoming.
38. D?Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer. JAMA 299(3): 289-295.
39. Granfors T, Modig H, Damber J-E, Tomic R (1998) Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or wit hout pelvic lymph node involvement: A prospective randomized study. J Urol 159(6): 2030-2034.
40. Granfors T, Modig H, Damber J-E, Tomic R (2006) Long-term followup of a randomized study of locally adv anced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 176(2): 544-547.
41. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V , Horwitz EM, Lawton C, Rosenthal SA, Sandler HM (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiat ion Therapy Oncology Group Protocol 92-02. J Clin Oncol 21(21): 3972-3978.
42. Heemsbergen WD, Al-Mamgani A, Witte MG, Van Herk M, Pos FJ, Lebesque JV (2010) Urinary obstruction in prostate cancer p atients from the dutch trial (68 gy vs 78 gy): Relationships with local dose, acute effects, and baseline characteristics. Int J Radiat Oncol Biol Phys 78(1): 19-25.
43. Heidenreich A, Bellmunt J, Bolla M, Joni au S, Mason M, Matveev V, Mottet N, Schmid H-P, Van Der Kwast T, Wiegel T (2011) EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1): 61-71.
44. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414): 557.
45. Horwitz EM Bae K Hanks GE Porter A G rignon DJ Brereton HD Venkatesan V Lawton CA Rosenthal SA Sandler HM 2008 Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in loca lly advanced prostate cancerJ Clin Oncol 26 15 2497-2504.
46. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
47. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2): 106-130.
48. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L (2011) Radiotherapy and short-term androgen deprivation for localized prostate cancer. New Engl J Med 365(2): 107-118.
49. PTH Julian, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. The Cochrane Collaboration.
50. Kollmeier MA, Zelefsky MJ (2012) How to select the optimal therapy for early-stage prostate cancer. Crit Rev Oncol/Hematol 84: E6-e15.
51. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A (2008) Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1): 67-74.
52. Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M (2003) Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radio ther Oncol 68(3): 255-267.
53. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F (2004) The efficacy and sequencing of a short course of androgen suppression on freedom f rom biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171(3): 1137-1140.
54. Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD (1997) Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+ ) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys 38(5): 931-939.
55. Lawton CA, Winter K, Grignon D, Pilepich MV (2005) Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positiv e adenocarcinoma of the prostate: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 23(4): 800-807.
56. Lawton CA, Winter K, Murray K, Machtay M , Mesic JB, Hanks GE, Coughlin CT, Pilepich MV (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation thera py for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49(4): 937-946.
57. Lu G, Ades A (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Statist Med 23(20): 3105-3124.
58. Lu G, Ades A (2006) Assessing evidence inconsistency in mixed treatment comparisons. J Am Statist Assoc 101: 447-459.
59. Lukka H, Hayter C, Julia n JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23(25): 6132-6138.
60. Lumley T (2002) Network meta-analysis for indirect treatment comparisons. Statist Med 21(16): 2313-2324.
61. Marzi S, Saracino B, Petrongari MG, Arcangeli S, Gomellini S, Arcangeli G, Benassi M, Landoni V (2009) Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: Conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res 28: 117.
62. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100(24): 1780-1791.
63. Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, Bahary J-P, Morton GC, Parliament MB, Sandler HM (2013) Preliminary toxicity analysis of 3-dim ensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 87(5): 932-938.
64. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid H-P, Van Der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and ca stration-resistant prostate cancer. Actas Urológicas Espan?olas 35(10): 565-579.
65. Nguyen LN, Pollack A, Zagars GK (1998) Late effects after radiotherapy for prostate cancer in a randomized dose-response stu dy: Results of a self-assessment questionnaire. Urology 51(6): 991-997.
66. Norkus D Miller A Kurtinaitis J Haverkamp U Popov S Prott F-J Valuckas KP 2009a A randomized trial compar ing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma Strahlentherapie Und Onkologie 185 11 715-721.
67. Norkus D, Miller A, Plie skiene A, Janulionis E, Valuckas KP (2009b ) A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: A report on the first-y ear biochemical response. Medicina (Kaunas 45(6): 469-475.
68. Peeters ST, Heemsbergen WD, Koper PC, Van PuttenWL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV (2006) Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13): 1990-1996.
69. Peeters ST, Heemsbergen WD, v an Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper P (2005) Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Onc ol Biol Phys 61(4): 1019-1034.
70. Pilepich M, Caplan R, Byhardt R, Lawton C, Gallagher M, Mesic J, Hanks G, Coughlin C, Porter A, Shipley W (1997) Phase III trial of androgen suppres sion using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15(3): 1013-1021.
71. Pilepich MV, S ause WT, Shipley WU, Krall JM, Lawton CA, Grignon D, Al-Sarraf M, Abrams RA, Caplan R, John MJ (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45(4): 616-623.
72. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D (2001) Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50(5): 1243-1252.
73. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-ter m results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61(5): 1285-1290.
74. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, Stoyanova R, Movsas B, Greenberg RE, Uzzo RG (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31(31): 3860-3868.
75. Pollack A, Zagars GK, Smith LG, Lee JJ, Von Eschenbach AC, Antolak JA, Starkschall G, Rosen I (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18(23): 3904-3911.
76. Pollac k A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, Von Eschenbach AC, Kuban DA, Rosen I (2002) Prostate cancer radiation dose response: Results of the MD Anderson phase III randomized trial. Int J Rad iat Oncol Biol Phys 53(5): 1097-1105.
77. Pollack A, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL, Rosen II (1996) Conventional vs conformal radiotherapy for prostate cancer: Preli minary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 34(3): 555-564.
78. Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term result s of RTOG 8610. J Clin Oncol 26(4): 585-591.
79. Roach III M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4): 965-974.
80. Salanti G, Higgins JP , Ades A, Ioannidis JP (2008) Evaluation of networks of randomized trials. Statist Methods Med Res 17(3): 279-301.
81. Salanti G, Marinho V, Higgins J (2009) A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol 62(8): 857-864.
82. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in nodenegative locally advanced cancer of the prostate. J Clin Oncol 23(6): 1192-1199.
83. S hipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ (1995) Advanced prostate cancer: The results of a randomized comparative trial of high dose irradia tion boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32(1): 3-12.
84. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1): 11-30.
85. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A (2002) Bayesian measures of model complexity and fit. J Royal Statist Soc B 64(4): 583-639.
86. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I (2000) Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48(3): 635-642.
87. Strigari L, Arcangeli G, Arcangeli S, Benassi M (2009) Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy cour ses for prostate cancer. Int J Radiat Oncol Biol Phys 73(5): 1454-1460.
88. Trikalinos TA Ioannidis J 2001 Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data J Clin Epidemiol 54 3 245-252.
89. Viani GA, Stefano EJ, Afonso SL (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trial s. Int J Radiat Oncol Biol Phys 74(5): 1405-1418.
90. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J (2011) Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: Final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81(5): 1271-1278.
91. Yeoh EE, Fraser RJ, McGowan RE, Botten RJ, Di Matteo AC, Roos DE, Penniment MG, Borg MF (2003) Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: Early results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys 55(4): 943-955.
92. Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, Weerasinghe S, Abeysinghe P (2006) Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated resu lts of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66(4): 1072-1083.
93. Zagars GK, Johnson DE, Von Eschenbach AC, Hussey DH (1988) Adjuvant estrogen following radiation therapy for stag e C adenocarcinoma of the prostate: Long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 14(6): 1085-1091.
94. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncolo gy Group/American College of Radiology 95-09. J Clin Oncol 28(7): 1106-1111.
95. Zietman AL, DeSilvio ML, Slater JD, Rossi Jr CJ, Miller DW, Adams JA, Shipley WU (2005) Comparison of convent ional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294(10): 1233-1239.